Company Profile
Pfizer Inc. is a global biopharmaceutical powerhouse headquartered at 66 Hudson Boulevard East, New York, NY 10001-2192. Incorporated in Delaware with the IRS Employer Identification Number 13-5315170, Pfizer has established itself as a cornerstone of the healthcare industry. With a legacy spanning over 170 years, the company is renowned for its commitment to discovering, developing, and delivering innovative medicines and vaccines that address some of the world’s most pressing health challenges. As of February 20, 2025, Pfizer had 5,667,340,414 shares of common stock outstanding, reflecting its significant market presence. The company’s common stock and 1.000% Notes due 2027 are traded on the New York Stock Exchange under the symbols PFE and PFE27, respectively, with an aggregate market value of voting stock held by non-affiliates estimated at approximately $158 billion as of the last business day of its most recently completed second fiscal quarter.
Pfizer operates globally, with a presence in both developed and emerging markets. Developed markets include Western Europe, Japan, Canada, Central Europe, Australia, Scandinavian countries, South Korea, the Balkans, New Zealand, and Finland. Emerging markets encompass Asia (excluding Japan and South Korea), Latin America, Africa, the Middle East, Eastern Europe (excluding the Balkans), and Turkey. This extensive global footprint allows Pfizer to address diverse healthcare needs across various regions, leveraging its expertise in biopharmaceuticals to improve patient outcomes worldwide.
The company’s operations are guided by a commitment to innovation, with a focus on advancing medical science through research and development (R&D). Pfizer’s business model integrates commercial operations, R&D, and strategic collaborations to bring cutting-edge therapies to market. Its global operations are supported by a robust supply chain managed by Pfizer Global Supply (PGS) and a contract manufacturing business, Pfizer CentreOne (PC1). Pfizer also engages in co-promotion and alliance agreements with companies like BioNTech, Astellas, and others, enhancing its ability to deliver high-impact healthcare solutions.
Products and Services
Pfizer’s portfolio is centered on its Global Biopharmaceuticals Business (Biopharma), which focuses on developing and commercializing prescription medicines and vaccines. The company’s offerings span multiple therapeutic areas, including oncology, infectious diseases, cardiology, neurology, and rare diseases. Below is an overview of key products and services:
Vaccines
- Prevnar Family (Prevnar 13/Prevenar 13 and Prevnar 20/Apexxnar): These vaccines protect against pneumococcal diseases, targeting both pediatric and adult populations. Prevnar 20, for instance, is designed to provide broader protection against additional pneumococcal serotypes.
- Comirnaty: Developed in collaboration with BioNTech, Comirnaty is a COVID-19 vaccine based on mRNA technology. Variants include formulations for 2023-2024 and 2024-2025, addressing evolving strains such as Omicron BA.4/BA.5, XBB.1.5, JN.1, and KP.2. It is authorized for emergency use in various regions and fully approved in others for preventing COVID-19.
Therapeutics
- Paxlovid: An oral antiviral treatment for COVID-19, consisting of nirmatrelvir and ritonavir tablets. Paxlovid is used to treat mild-to-moderate COVID-19 in patients at high risk of progression to severe disease.
- Vyndagel Family (Vyndagel, Vyndamax, Vynmac): These medications treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare condition affecting the heart. They are critical for patients with this progressive disease, improving quality of life and survival rates.
- Oncology Portfolio: Pfizer has a robust oncology division, offering treatments for metastatic colorectal cancer (mCRC), metastatic castration-resistant prostate cancer (mCRPC), metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC), non-metastatic castration-sensitive prostate cancer (nmCSPC), renal cell carcinoma (RCC), and metastatic cervical cancer (mCC). The acquisition of Seagen Inc. has bolstered its antibody-drug conjugate (ADC) capabilities, enhancing targeted cancer therapies.
- Rare Disease Treatments: Pfizer addresses conditions like Duchenne muscular dystrophy (DMD) through innovative therapies, leveraging acquisitions like Global Blood Therapeutics (GBT).
- Inflammatory Diseases: Treatments for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC) are part of Pfizer’s portfolio, addressing chronic inflammatory conditions.
Other Services
Beyond its core biopharmaceutical products, Pfizer offers contract manufacturing through Pfizer CentreOne (PC1), which provides high-quality manufacturing services for sterile injectables and active pharmaceutical ingredients (APIs). The company also engages in strategic alliances, co-promotion agreements, and joint ventures, such as the GSK Consumer Healthcare JV and collaborations with Biohaven, Genmab, and Pierre Fabre, to expand its market reach and innovation capabilities.
Brand Details
Pfizer’s brand portfolio is a mix of globally recognized prescription medicines, vaccines, and legacy off-patent brands. Key brands include:
- Comirnaty: A flagship mRNA-based COVID-19 vaccine, co-developed with BioNTech, widely recognized for its role in combating the global pandemic.
- Paxlovid: An oral COVID-19 treatment that has gained prominence for its efficacy in reducing severe outcomes in high-risk patients.
- Prevnar Family: A leading pneumococcal vaccine brand, with Prevnar 13 and Prevnar 20 being trusted names in pediatric and adult immunization.
- Vyndagel Family: Includes Vyndagel, Vyndamax, and Vynmac, known for their targeted approach to treating ATTR-CM.
- Legacy Brands (Upjohn Business): Although the Upjohn Business, which included off-patent brands like Lipitor, Lyrica, Norvasc, Celebrex, and Viagra, was spun off in 2020 to form Viatris, Pfizer continues to benefit from certain co-promotion agreements and retains brand equity in these names in specific markets.
Pfizer’s branding strategy emphasizes innovation, trust, and global accessibility, positioning its products as critical solutions for both common and rare medical conditions. The company’s focus on mRNA technology and oncology has further strengthened its reputation as a leader in cutting-edge healthcare solutions.
Board of Directors
Pfizer’s Board of Directors comprises a diverse group of leaders with expertise in healthcare, finance, technology, and governance. As of February 27, 2025, the board includes the following members:
- Albert Bourla: Chairman, Chief Executive Officer, and Director. Dr. Bourla leads Pfizer’s strategic vision, driving innovation and global growth.
- Ronald E. Blaylock: Director, bringing expertise in finance and investment management.
- Mortimer J. Buckley: Director, known for his leadership in asset management.
- Susan Desmond-Hellmann: Director, with a background in oncology and global health.
- Joseph J. Echevarria: Director, offering insights from his extensive experience in accounting and corporate governance.
- Scott Gottlieb: Director, a former FDA Commissioner with deep expertise in healthcare policy and regulation.
- Helen H. Hobbs: Director, a renowned scientist specializing in genetics and metabolism.
- Susan Hockfield: Director, with expertise in neuroscience and academic leadership.
- Dan R. Littman: Director, an immunologist contributing to Pfizer’s scientific strategy.
- Shantanu Narayen: Director, known for his leadership in technology and digital transformation.
- Suzanne Nora Johnson: Director, with experience in finance and corporate governance.
- James Quincey: Director, bringing global business leadership from the consumer goods sector.
- James C. Smith: Director, offering expertise in media and corporate strategy.
- Cyrus Taraporevala: Director, with a background in investment management and financial services.
The board is supported by robust corporate governance practices, including Pfizer’s Corporate Governance Principles, Director Qualification Standards, and a Code of Business Conduct and Ethics. These policies ensure transparency, accountability, and ethical decision-making, with further details available on Pfizer’s website or upon request from the Corporate Secretary.
Subsidiaries
Pfizer operates through a network of subsidiaries that enhance its global operations, manufacturing, and R&D capabilities. Key subsidiaries include:
- Pfizer Investment Enterprises Pte. Ltd. (PIE): A wholly-owned finance subsidiary based in Singapore, facilitating Pfizer’s financial operations and debt issuances.
- Seagen Inc.: Acquired to strengthen Pfizer’s oncology portfolio, particularly in antibody-drug conjugates (ADCs).
- Hospira, Inc.: A leader in sterile injectables and biosimilars, enhancing Pfizer’s manufacturing capabilities.
- Wyeth LLC: A subsidiary focused on pharmaceuticals, contributing to Pfizer’s legacy brands and R&D efforts.
- Meridian Medical Technologies, Inc.: Specializes in auto-injector technologies, such as epinephrine delivery systems.
- Global Blood Therapeutics, Inc. (GBT): Focused on rare diseases, particularly sickle cell disease and DMD.
- Arena Pharmaceuticals, Inc.: Enhances Pfizer’s portfolio in immunology and inflammation.
- Biohaven Pharmaceutical Holding Company Limited: Contributes to Pfizer’s neurology portfolio, particularly in migraine treatments.
- ReViral Ltd.: Focused on respiratory syncytial virus (RSV) therapies, bolstering Pfizer’s infectious disease offerings.
These subsidiaries, among others, enable Pfizer to maintain a diversified portfolio and global reach. The company’s subsidiaries are integral to its operations, with financial statements of unconsolidated subsidiaries omitted from public filings as they do not constitute significant subsidiaries in aggregate.
Financial Overview
Pfizer’s financial performance reflects its position as a leading global biopharmaceutical company. Below are the consolidated financial statements, including the Profit and Loss Statement, Balance Sheet, and Cash Flow Statement, based on typical structures for a company of Pfizer’s scale. Note that specific figures for 2024 are not fully provided in the document, so I will include placeholders and assumptions where necessary, ensuring alignment with standard financial reporting practices.
Consolidated Profit and Loss Statement (For the Year Ended December 31, 2024)
The Profit and Loss Statement summarizes Pfizer’s revenues, expenses, and net income. Below is a hypothetical structure based on typical pharmaceutical industry metrics and Pfizer’s operations:
| Item | Amount (in millions USD) |
|---|---|
| Revenues | $60,000 |
| Sales of Biopharmaceutical Products | $55,000 |
| Alliance Revenues (e.g., BioNTech, Astellas) | $4,000 |
| Other Income (e.g., Licensing, Royalties) | $1,000 |
| Cost of Sales | $18,000 |
| Gross Profit | $42,000 |
| Operating Expenses | $30,000 |
| Research and Development (R&D) | $10,000 |
| Selling, General, and Administrative (SG&A) | $15,000 |
| Amortization of Intangible Assets | $3,000 |
| Other Operating Expenses | $2,000 |
| Operating Income | $12,000 |
| Other Income/(Expense) | ($1,000) |
| Interest Expense | ($1,500) |
| Other Non-Operating Income | $500 |
| Income Before Taxes | $11,000 |
| Provision for Taxes | $2,200 |
| Net Income | $8,800 |
| Earnings Per Share (EPS) | $1.55 |
Note: Figures are illustrative, as specific 2024 financial data was not provided. Actual revenues may be driven by key products like Comirnaty, Paxlovid, and the Prevnar family, with expenses reflecting significant R&D investment and global operations.
Consolidated Balance Sheet (As of December 31, 2024)
The Balance Sheet provides a snapshot of Pfizer’s assets, liabilities, and equity. Below is a hypothetical structure:
| Item | Amount (in millions USD) |
|---|---|
| Assets | |
| Current Assets | $30,000 |
| Cash and Cash Equivalents | $5,000 |
| Short-Term Investments | $3,000 |
| Accounts Receivable | $10,000 |
| Inventories | $8,000 |
| Other Current Assets | $4,000 |
| Non-Current Assets | $100,000 |
| Property, Plant, and Equipment (PP&E) | $15,000 |
| Intangible Assets (e.g., Patents, Goodwill) | $60,000 |
| Long-Term Investments | $10,000 |
| Other Non-Current Assets | $15,000 |
| Total Assets | $130,000 |
| Liabilities | |
| Current Liabilities | $25,000 |
| Accounts Payable | $5,000 |
| Short-Term Debt | $10,000 |
| Other Current Liabilities | $10,000 |
| Non-Current Liabilities | $50,000 |
| Long-Term Debt | $35,000 |
| Deferred Tax Liabilities | $10,000 |
| Other Non-Current Liabilities | $5,000 |
| Total Liabilities | $75,000 |
| Equity | |
| Common Stock | $283 |
| Additional Paid-In Capital | $90,000 |
| Retained Earnings | $50,000 |
| Accumulated Other Comprehensive Income | ($5,000) |
| Total Equity | $55,000 |
| Total Liabilities and Equity | $130,000 |
Note: Figures are illustrative, with common stock calculated based on 5,667,340,414 shares at $0.05 par value. Intangible assets reflect acquisitions like Seagen and Hospira, while debt aligns with indentures noted in the document.
Consolidated Cash Flow Statement (For the Year Ended December 31, 2024)
The Cash Flow Statement tracks cash inflows and outflows. Below is a hypothetical structure:
| Item | Amount (in millions USD) |
|---|---|
| Cash Flows from Operating Activities | |
| Net Income | $8,800 |
| Adjustments for Non-Cash Items | $5,000 |
| Depreciation and Amortization | $4,000 |
| Changes in Working Capital | ($2,000) |
| Net Cash Provided by Operating Activities | $15,800 |
| Cash Flows from Investing Activities | |
| Purchases of PP&E | ($3,000) |
| Acquisitions (e.g., Seagen) | ($10,000) |
| Proceeds from Sale of Assets | $1,000 |
| Net Cash Used in Investing Activities | ($12,000) |
| Cash Flows from Financing Activities | |
| Proceeds from Debt Issuance | $5,000 |
| Repayment of Debt | ($3,000) |
| Dividends Paid | ($4,000) |
| Share Repurchases | ($1,000) |
| Net Cash Used in Financing Activities | ($3,000) |
| Net Increase in Cash | $800 |
| Cash and Cash Equivalents, Beginning | $4,200 |
| Cash and Cash Equivalents, Ending | $5,000 |
Note: Figures are illustrative, reflecting Pfizer’s typical cash flow patterns, including significant R&D and acquisition investments, debt management, and shareholder returns.
Strategic Operations and Global Impact
Pfizer’s operations are structured to maximize innovation and global reach. The company’s Research and Development (R&D) efforts are led by its Oncology Research and Development (ORD) and Pfizer Research and Development (PRD) units, focusing on breakthrough therapies in oncology, infectious diseases, and rare disorders. Strategic collaborations with companies like BioNTech, Astellas, and Genmab enhance Pfizer’s ability to develop and commercialize innovative treatments.
Pfizer’s global supply chain, managed by Pfizer Global Supply (PGS), ensures the efficient production and distribution of its products. The company adheres to current Good Manufacturing Practices (cGMP) and works closely with regulatory bodies like the FDA, EMA, and WHO to maintain high standards. Pfizer also navigates complex pricing pressures and government regulations, such as the Inflation Reduction Act of 2022 (IRA) and the Medicare Drug Price Negotiation Program (MDPNP), to ensure accessibility while maintaining profitability.
The company’s commitment to corporate social responsibility is evident in its environmental initiatives and workforce policies. Pfizer employs thousands globally, fostering a culture of innovation and diversity. Its environmental efforts focus on sustainability, addressing raw material sourcing and waste management to minimize its ecological footprint.
Challenges and Opportunities
Pfizer faces challenges such as pricing pressures from managed care organizations (MCOs) and pharmacy benefit managers (PBMs), as well as competition in the biopharmaceutical industry. Regulatory constraints, including the 340B Drug Pricing Program and volume-based procurement (VBP) in emerging markets, impact pricing strategies. However, opportunities abound, particularly in oncology, mRNA technology, and rare disease treatments, where Pfizer’s acquisitions and R&D investments position it for growth.
Conclusion
Pfizer Inc. stands as a global leader in biopharmaceuticals, driven by its commitment to innovation, a diverse portfolio of medicines and vaccines, and a robust global presence. With iconic brands like Comirnaty, Paxlovid, and Prevnar, a distinguished board of directors, and a network of strategic subsidiaries, Pfizer continues to shape the future of healthcare. Its financial strength, supported by significant revenues and strategic investments, underscores its ability to address global health challenges while delivering value to shareholders and patients alike.
Frequently Asked Questions About Pfizer Inc.
What does Pfizer Inc. do?
Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, and distributes prescription medicines and vaccines. Its portfolio includes treatments for oncology, infectious diseases, cardiology, and rare diseases, as well as contract manufacturing services through Pfizer CentreOne.
What are some of Pfizer’s key products?
Pfizer’s key products include the Comirnaty COVID-19 vaccine, Paxlovid antiviral treatment, the Prevnar family of pneumococcal vaccines, and the Vyndagel family for transthyretin amyloid cardiomyopathy. The company also offers oncology and rare disease treatments.
Where is Pfizer headquartered?
Pfizer is headquartered at 66 Hudson Boulevard East, New York, NY 10001-2192, USA.
Who leads Pfizer’s Board of Directors?
Dr. Albert Bourla serves as the Chairman, Chief Executive Officer, and Director of Pfizer, leading the company’s strategic direction and overseeing its board.
What are some of Pfizer’s major subsidiaries?
Pfizer’s major subsidiaries include Seagen Inc. (oncology), Hospira, Inc. (sterile injectables), Wyeth LLC (pharmaceuticals), Global Blood Therapeutics (rare diseases), and Biohaven Pharmaceutical (neurology).
How does Pfizer contribute to global healthcare?
Pfizer contributes to global healthcare through innovative medicines and vaccines, strategic partnerships with companies like BioNTech, and a robust supply chain ensuring product availability in developed and emerging markets.
What is Pfizer’s approach to research and development?
Pfizer invests heavily in R&D, focusing on oncology, infectious diseases, and rare disorders. Its efforts are supported by units like Oncology Research and Development (ORD) and collaborations with academic and industry partners.
What brands are associated with Pfizer?
Pfizer’s notable brands include Comirnaty, Paxlovid, Prevnar 13/20, and Vyndagel/Vyndamax. The company also retains legacy brand equity in products like Lipitor and Viagra in certain markets.
How does Pfizer ensure product quality?
Pfizer adheres to current Good Manufacturing Practices (cGMP) and works with regulatory bodies like the FDA and EMA to maintain high-quality standards across its global supply chain, managed by Pfizer Global Supply (PGS).
Where can I find more information about Pfizer’s financial performance?
For detailed financial information, visit Pfizer’s official website or contact their Corporate Secretary at 66 Hudson Boulevard East, New York, NY 10001-2192.
